All Content Outsourced Pharma

  1. February 2026 — CDMO Opportunities And Threats Report 3/20/2026

    Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

  2. COGs And Biology, Two Endpoints Needlessly At Odds In Advanced Therapy 3/20/2026

    Problems emerge when development, manufacturing, and clinical priorities fail to converge in cell and gene therapy development.

  3. UK's Decentralized Manufacturing Could Be A Revolution; Mind The Risk 3/20/2026

    Decentralized manufacture will only improve patient outcomes if the pharmaceutical quality system at the control site is strong enough to carry the weight of the network.

  4. Asimov Launches RNA Edge, A Lab-In-The-Loop Platform For AI Optimization Of RNA Therapeutic Candidates 3/19/2026

    Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, announces the launch of its RNA Edge System, an integrated AI, synthetic biology, and laboratory platform to optimize RNA therapies.

  5. The Long Road To U.S. Vaccine Manufacturing 3/19/2026

    GeoVax CEO David Dodd sings the praises and is grateful for the program-enabling relationships he has in Europe. At the same time, he harbors lingering disappointment. From the outset of its formation, the biotech has desired to work with U.S.-based CDMOs.  But he says he will not give up. “One way or the other,” Dodd says, “GeoVax will have U.S.-based manufacturing.”

  6. Pyramid Pharma Services Signs Commercial Agreement With A Top 3 Global Pharma Innovator To Support siRNA Injectable Therapy 3/19/2026

    Pyramid Pharma Services, a U.S.-based contract development and manufacturing organization (CDMO) specializing in sterile fill-finish manufacturing and integrated drug product services—including device assembly, labeling, and packaging—for injectable therapies, today announced that it has entered into a five-year commercial supply agreement with a leading global pharmaceutical company to support the commercial manufacture of a small interferon RNA (siRNA) injectable therapy used to treat a rare genetic kidney disease.

  7. All The Ways Global Biopharma Still Grapples With Annex 1 3/19/2026

    Biopharma companies can't consistently meet Annex 1 expectations. At the heart of the problems, regulators have shifted the burden of proof to manufacturers.

  8. Globalization vs. Localization: Where To Outsource In A Changing World 3/18/2026

    Geographical strategy for outsourcing is a pressing issue: balancing historical global supply chains with current pressures to reshore/nearshore parts of operations. In this fireside chat, editorial board members Lynn Cinelli, and Kent Pryor help us navigate the geographical pressures of modern outsourcing, the root causes of global supply chain breakdowns, the hardest assets to move across regions, and whether time-sensitive sponsors should simplify their chain or hunt for best-in-class partners globally.

  9. Choosing The Right Outsourcing Model (CRO vs. CDMO vs. FSP) 3/18/2026

    Many pharma companies are shifting from one-off, fee-for-service deals to deeper long-term partnerships with their CDMOs, emphasizing shared goals and transparency. In this episode, editorial board members Doug Bakan and Kim Burson discuss how to transform the sponsor-CDMO dynamic. 

  10. Strategic CDMO Partnerships: From Vendor To Collaborative Partner 3/18/2026

    Many pharma companies are shifting from one-off, fee-for-service deals to deeper long-term partnerships with their CDMOs, emphasizing shared goals and transparency. In this episode, editorial board members Doug Bakan and Kim Burson discuss how to transform the sponsor-CDMO dynamic.